文献速递皮肤感染

VP-102(含斑蝥素0.7%药物-器械组合)治疗儿童及成人传染性软疣的安全性与疗效:两项3期随机临床试验

Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
PubMed 文献 · JAMA Dermatol · 2020-01-01

两项设计相同的3期随机双盲溶媒对照试验(CAMP-1和CAMP-2)在美国31个中心纳入528例≥2岁传染性软疣患者,评估VP-102(含斑蝥素0.7% w/v)外用每21天一次最多4次的安全性和疗效。结果显示VP-102组完全清除率显著高于溶媒组(CAMP-1:46.3% vs 17.9%,P<.001;CAMP-2:54.0% vs 13.4%,P<.001),不良事件多为轻中度且局限于应用部位。

要点

  • VP-102每21天外用一次,最多4次,在两项3期试验中完全清除率显著优于溶媒(P<.001)。
  • 不良事件常见但多为轻中度,主要为应用部位水疱、疼痛、瘙痒、红斑和结痂。
  • VP-102可能为传染性软疣提供有效且安全的治疗选择,目前美国FDA尚无获批药物。

核心结论

  • VP-102在两项3期试验中均 statistically significantly superior to vehicle 达到传染性软疣病变完全清除,不良事件一般轻中度且局限于应用部位。
  • VP-102可能是传染性软疣有效且安全的治疗选择,该病目前无美国FDA获批治疗。

研究设计与样本

  • 两项3期、随机、双盲、溶媒对照试验(CAMP-1和CAMP-2),设计相同,在美国31个中心开展。
  • 共528例≥2岁传染性软疣患者参与,527例接受治疗(CAMP-1 n=265;CAMP-2 n=262)。
  • 参与者按3:2随机接受VP-102或溶媒外用,每21天一次,直至病变完全清除或最多4次治疗。
  • 主要疗效终点为第84天研究结束时全部病变(基线及新发)完全清除的受试者比例,采用意向性分析。

主要发现

  • CAMP-1中VP-102组完全清除率为46.3%,溶媒组为17.9%(P<.001)。
  • CAMP-2中VP-102组完全清除率为54.0%,溶媒组为13.4%(P<.001)。
  • 不良事件发生率:VP-102组CAMP-1为99%、CAMP-2为95%;溶媒组CAMP-1为73%、CAMP-2为66%。
  • 最常见不良事件包括应用部位水疱、疼痛、瘙痒、红斑和结痂,多数为轻中度。

关键数值与推荐

  • 主要疗效终点:第84天研究结束时全部传染性软疣病变完全清除的受试者比例。
  • VP-102组完全清除率CAMP-1为46.3% vs 溶媒17.9%(P<.001);CAMP-2为54.0% vs 13.4%(P<.001)。
  • 给药方案:每21天外用一次,最多4次,直至病变完全清除。

临床怎么用

  • 对于≥2岁传染性软疣患者,可考虑VP-102每21天外用一次,最多4次,以达到病变完全清除。
  • 治疗期间需预期应用部位水疱、疼痛、瘙痒、红斑和结痂等局部反应,多为轻中度。
  • VP-102为传染性软疣提供了潜在的有效治疗选择,尤其在美国FDA无获批药物的情况下。

局限性

  • 原文摘要未报告局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Molluscum contagiosum (MC) is a common viral skin infection that primarily affects children. Cantharidin, a topical vesicant, has a long history of use for MC in compounded formulations, but the safety and efficacy of doses, regimens, and application methods have not been demonstrated in large-scale trials. OBJECTIVE: To determine the safety and efficacy of VP-102, a drug-device combination containing cantharidin, 0.7% (w/v), compared with vehicle in individuals with MC. DESIGN, SETTING, AND PARTICIPANTS: Two phase 3, randomized, double-blind, vehicle-controlled trials of identical design (Cantharidin Application in Molluscum Patients [CAMP-1 and CAMP-2]) were conducted in 31 centers across the US. A total of 528 individuals aged 2 years or older with MC participated. CAMP-1 was conducted from March 21 to November 26, 2018, and CAMP-2 was conducted from February 14 to September 26, 2018. INTERVENTIONS: Participants were randomized (3:2) to topical application of VP-102 or vehicle to all treatable lesions every 21 days until complete lesion clearance or up to 4 treatments. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the proportion of VP-102-treated participants achieving complete clearance of all MC lesions (baseline and new) compared with those who received the vehicle at the end-of-study visit on day 84. Intent-to-treat analysis was conducted for the efficacy population. Secondary efficacy outcomes included the proportion of participants achieving complete clearance of lesions at days 21, 42, and 63. Safety outcomes included assessment of adverse events, including expected local skin reactions. RESULTS: Of the 528 participants enrolled, 527 received treatment (CAMP-1, n = 265; CAMP-2, n = 262). A total of 267 of 527 participants (50.7%) were male; mean (SD) ages for CAMP-1 and CAMP-2 were 7.5 (5.3) years and 7.4 (8.0) years for the VP-102 groups and 6.3 (4.7) years and 7.3 (6.7) years for the vehicle groups. Treatment with VP-102 demonstrated superior efficacy to vehicle in the percentage of participants with complete clearance of MC lesions at the end of the study visit for CAMP-1 (VP-102: 46.3% vs vehicle: 17.9%; P < .001) and CAMP-2 (VP-102: 54.0% vs vehicle: 13.4%; P < .001). Adverse events were observed in 99% (CAMP-1) and 95% (CAMP-2) of VP-102-treated participants and 73% (CAMP-1) and 66% (CAMP-2) of vehicle-treated participants. The most common adverse events included application site vesicles, pain, pruritus, erythema, and scab. Most adverse events were mild or moderate in severity. CONCLUSIONS AND RELEVANCE: In the 2 phase 3 trials reported herein, VP-102 was statistically significantly superior to vehicle in achieving complete clearance of MC lesions at the end of the study visit in both trials, with adverse events that were generally mild to moderate and confined to application sites. These findings show that VP-102 is potentially an effective and safe treatment for MC, a common skin condition with no US Food and Drug Administration-approved treatments. TRIAL REGISTRATIONS: ClinicalTrials.gov Identifiers: NCT03377790 and NCT03377803.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Eichenfield LF, McFalda W, Brabec B, et al. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020. PMID: 32965495. doi:10.1001/jamadermatol.2020.3238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。